Contralateral Testicular Biopsy in Men with Testicular Cancer

IF 5.4 3区材料科学 Q2 CHEMISTRY, PHYSICAL

ACS Applied Energy Materials Pub Date : 2024-05-01 DOI:10.1016/j.euf.2024.06.006

John Pfail , Ines Santiago , Thomas L. Jang , Pia Paffenholz , EAU-YAU Penile and Testis Cancer Working Group

{"title":"Contralateral Testicular Biopsy in Men with Testicular Cancer","authors":"John Pfail , Ines Santiago , Thomas L. Jang , Pia Paffenholz , EAU-YAU Penile and Testis Cancer Working Group","doi":"10.1016/j.euf.2024.06.006","DOIUrl":null,"url":null,"abstract":"<div><p>Testicular germ cell tumors (TGCTs) are an uncommon disease accounting for roughly 1% of newly diagnosed cancers in men worldwide. Incidence rates vary from 7 to 10 per 100000 males in Europe and North America. Approximately 2–5% of patients with unilateral TGCT will also harbor germ cell neoplasia in situ (GCNIS) in the contralateral testicle, which may progress to cancer in at least 50% of individuals. The question of whether routine contralateral testicular biopsy should be performed in patients with testicular cancer to detect the presence of GCNIS remains controversial. Screening and treatment of GCNIS are warranted only if the patient’s outcome will be improved and there will be little impact on testicular function. In this review, we evaluate current guideline recommendations and the issues concerning contralateral testicular biopsy.</p></div><div><h3>Patient summary</h3><p>Among men with cancer in one testicle, about 2–5% will also have cells with cancerous potential, called germ cell neoplasia in situ (GCNIS), in the other testicle. This mini-review discusses issues related to routine biopsy of the other testicle and the risk factors and treatment options for GCNIS in men with testicular cancer.</p></div>","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":null,"pages":null},"PeriodicalIF":5.4000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405456924000956/pdfft?md5=1fadf413978b0536ac0722ade0973ed7&pid=1-s2.0-S2405456924000956-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Energy Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405456924000956","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Testicular germ cell tumors (TGCTs) are an uncommon disease accounting for roughly 1% of newly diagnosed cancers in men worldwide. Incidence rates vary from 7 to 10 per 100 000 males in Europe and North America. Approximately 2–5% of patients with unilateral TGCT will also harbor germ cell neoplasia in situ (GCNIS) in the contralateral testicle, which may progress to cancer in at least 50% of individuals. The question of whether routine contralateral testicular biopsy should be performed in patients with testicular cancer to detect the presence of GCNIS remains controversial. Screening and treatment of GCNIS are warranted only if the patient’s outcome will be improved and there will be little impact on testicular function. In this review, we evaluate current guideline recommendations and the issues concerning contralateral testicular biopsy.

Patient summary

Among men with cancer in one testicle, about 2–5% will also have cells with cancerous potential, called germ cell neoplasia in situ (GCNIS), in the other testicle. This mini-review discusses issues related to routine biopsy of the other testicle and the risk factors and treatment options for GCNIS in men with testicular cancer.

查看原文本刊更多论文

睾丸癌男性患者的对侧睾丸活检。

睾丸生殖细胞肿瘤（TGCT）是一种不常见的疾病，约占全球男性新诊断癌症的 1%。在欧洲和北美，发病率为每 10 万名男性中有 7 到 10 例。约有 2%-5% 的单侧 TGCT 患者的对侧睾丸也存在生殖细胞原位瘤（GCNIS），其中至少 50% 的患者可能发展为癌症。关于是否应对睾丸癌患者的对侧睾丸进行常规活检以检测是否存在 GCNIS 的问题仍存在争议。只有在患者的预后得到改善且对睾丸功能影响不大的情况下，才有必要对 GCNIS 进行筛查和治疗。在这篇综述中，我们评估了目前的指南建议以及有关对侧睾丸活检的问题。患者摘要：在一侧睾丸罹患癌症的男性中，约有 2%-5% 的患者的另一侧睾丸也存在具有癌变潜能的细胞，即生殖细胞原位瘤（GCNIS）。这篇微型综述讨论了与另一个睾丸常规活检相关的问题，以及男性睾丸癌患者 GCNIS 的风险因素和治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Energy Materials Materials Science-Materials Chemistry

CiteScore

10.30

自引率

6.20%

发文量

1368

期刊介绍： ACS Applied Energy Materials is an interdisciplinary journal publishing original research covering all aspects of materials, engineering, chemistry, physics and biology relevant to energy conversion and storage. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrate knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important energy applications.